Underwriter (Number of Offerings As Lead Underwriter/ Number of Offerings As Lead Or Co-Manager) Gross Proceeds (M) Rodman & Renshaw (0/4) $1,281.1 Lazard Capital Markets (1/6) $1,250.0 Citigroup (1/2) $1,080.0 CIBC World Markets (5/10) $1,061.4 Friedman Billings Ramsay (0/1) $1,032.0 Lehman Brothers (4/6) $992.7 UBS Investment Bank (10/11) $984.2 Banc of America Securities (8/10) $753.8 Pacific Growth Equities (4/11) $727.7 Wachovia Capital Markets (0/1) $400.7
State of the Industry Report | Tuesday, June 5, 2007
Company* (Symbol) Product Description Indication Action/Date Aastrom Biosciences Inc. (ASTM) Tissue Repair Cells Autologous bone marrow-derived adult stem and progenitor cells Osteonecrosis The FDA granted orphan designation to the product in that indication, for which studies were being planned (3/23) Agennix Inc.* Talactoferrin Oral talactoferrin alfa solution Renal cell carcinoma The FDA granted orphan designation to the product in that indication (10/12) Allos Therapeutics Inc
State of the Industry Report | Monday, June 4, 2007
Company* (Symbol) Product Description Indication Action/Date Abbott Laboratories (NYSE ABT) Humira (FDA-approved) Adalimumab fully human antibody designed to block TNF-alpha Ankylosing spondylitis The product was approved in Europe for treating severe, active ankylosing spondylitis (6/7) Health Canada granted marketing approval (11/6) Abraxis BioScience Inc. (ABBI) Abraxane (FDA-approved) Paclitaxel protein-bound particles for injection albumin-bound Metastatic breast cancer The
State of the Industry Report | Monday, June 4, 2007
Company* (Symbol) Product Description Indication Action/Date Abraxis BioScience Inc. (ABBI) Abraxane Paclitaxel protein-bound particles for injection albumin-bound Breast cancer FDA advisory panel recommended against approval for use in the adjuvant treatment of node-positive breast cancer (9/7) Adeza Biomedical Corp. (ADZA) the PDUFA date is Oct. 20 (8/29) Gestiva Long-acting form of a naturally occurring progesterone Prevention of preterm birth An FDA advisory panel voted that
State of the Industry Report | Monday, June 4, 2007
Company* (Symbol) Product Description Indication Action/Date Acambis plc (UK ACAM) ACAM2000 Second-generation vaccine Smallpox infection Submitted first portion of a BLA under a rolling application (1/18) completed submission of BLA (4/18) Adeza Biomedical Corp. (ADZA) Gestiva Long-acting form of a naturally occurring progesterone Prevention of preterm birth The FDA accepted the NDA for filing (7/6) an FDA advisory panel will review the NDA Aug. 29 (7/18) Adolor Corp. (ADLR) and
State of the Industry Report | Monday, June 4, 2007
Company* (Symbol) Product Description Indication Action/Date Amgen Inc. (AMGN) Aranesp (FDA-approved) Darbepoetin alfa, a recombinant erythropoietic protein Anemia in chronic kidney disease FDA issued an approvable letter that requests additional data for the once-monthly dosing regimen, including an additional clinical study (10/13) Avanir Pharmaceuticals Inc. (AVNR) Zenvia (formerly Neurodex) Oral combination of dextromethorphan and an enzyme inhibitor, quinidine Involuntary
State of the Industry Report | Monday, June 4, 2007
Company* (Symbol) Product Description Indication Action/Date Abbott Laboratories Humira (FDA-approved) Adalimumab fully human antibody designed to block TNF-alpha Ankylosing spondylitis psoriatic arthritis The FDA approved the drug for the additional indication of reducing signs and symptoms in those with active AS (7/31) FDA approved an expanded label that includes inhibiting structural joint damage and improving physical function (11/14) Access Pharmaceuticals Inc. (AMEX AKC) MuGard
State of the Industry Report | Monday, June 4, 2007
Biotech Co.* (Country Symbol) Agbiotech Partner (Country Symbol) Type/Product Area Terms/Details (Date) Avant Immuno-therapeutics Inc. (AVAN) Pfizer Inc. They extended deal to develop animal vaccines based on Avant technologies Pfizer is funding the program to develop prophylactic and therapeutic vaccines to protect livestock and companion animals from respiratory and enteric diseases terms of the deal were not disclosed (10/4) Avidis SA* (France) Novartis Animal Health (Switzerland
State of the Industry Report | Monday, June 4, 2007
Company* (Symbol) University/ Non-Profit Type Of Agreement Product Area Details (Date) FIRST QUARTER Affymetrix Inc. (AFFX) Duke University Collaboration Five-year deal to analyze genomic information across large patient samples Duke researchers will use Affy-metrix microarray technology to develop new applications for translational research projects the initial focus is on cancer and cardiovascular disease (1/9) Affymetrix Inc. (AFFX) Korea’s National Institute of Health Agreement
State of the Industry Report | Monday, June 4, 2007
Company* (Country Symbol) Company (Country) Type/Product Area Terms/Details (Date) FIRST QUARTER Acorda Therapeutics Inc.* Paul Royalty Fund Paul Royalty purchased a portion of the future revenues of the approved spasticity products Zanaflex Capsules and Zanaflex tablets Acorda received $15M and could receive two payments of $5M each if sales milestones are reached (1/19) A.P. Pharma Inc. (APPA) Paul Royalty Fund The fund purchased future royalties on sales of the dermatology
State of the Industry Report | Monday, June 4, 2007
Company* (Country; Symbol) Company* (Country; Symbol) Product Terms/Details (Date) FIRST QUARTER Angel Biotechnology Holdings plc* (UK) ReNeuron Group plc (UK: LSE:RENE) Deal under which Angel will scale up ReNeuron’s ReN005 stem cell line for Huntington’s disease Terms of the contract were not disclosed (2/7) Cobra Bio-manufacturing plc (UK; AIMCBF) Replikun Biotech Pty. Ltd.* (Australia) Cobra will construct a cell line for the Replikun gene therapy system KUN-GMCSF Terms of the
State of the Industry Report | Monday, June 4, 2007
I. Modified Agreements Company* (Country Symbol) Company* (Country Symbol) Change from original agreement Terms/Details (Date) FIRST QUARTER Cellegy Pharmaceuticals Inc. (OTC BB CLGY) ProStrakan Group plc (UK LSE PSK) They renegotiated deal under which ProStrakan distributes the testosterone gel Tostrex in Europe ProStrakan will assume responsibility for manufacturing and product support and will purchase the product directly from the manufacturer Cellegy remains entitled to
State of the Industry Report | Monday, June 4, 2007
Company* (Country Symbol) Company* (Country Symbol) Type/Product Area Terms/Details (Date) FIRST QUARTER Aastrom Biosciences Inc. (ASTM) Orthovita Inc. (VITA) Collaboration to develop products for the orthopedics market They will use Orthovita’s matrices technology with Aastrom’s bone marrow-derived cells in the effort terms were not disclosed (3/20) ACE BioSciences A/S* (Denmark) Nordic Vaccine A/S* (Denmark) Deal to develop fast-acting vaccines that provide better protection and can
State of the Industry Report | Thursday, May 24, 2007
Biotech Co.* (Country Symbol) Pharma Co. (Country) Product Terms/Details (Date) FIRST QUARTER Align Pharmaceuticals Inc.* PDI Inc. Three-year deal under which PDI will provide marketing services for three oncology products from Align PDI initially will provide a sales team of 40 representatives the products are Numoisyn Lozenges and Numoisyn Liquid, for dry mouth, and Xclair, for radiation dermatitis (1/19) Amarillo Biosciences Inc. (OTC BB AMAR) Bumimedic Sdn. Bhd. (Malaysia part of
State of the Industry Report | Thursday, May 24, 2007
Biotech Co.* (Country Symbol) Pharma Co. (Country) Change from original agreement Terms/Details (Date) I. Modified Agreements FIRST QUARTER AEterna Zentaris Inc. (AEZS) Solvay Pharmaceuticals BV (Belgium) AEterna regained rights to cetrorelix for benign prostate hyperplasia except in Japan late-stage trials are planned Solvay is continuing development of the LHRH antagonist in gynecological indications no payment was made in the restructuring of the January 2004 deal (1/30) Biomira Inc
State of the Industry Report | Thursday, May 24, 2007
Biotech Co.* (Country Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date) FIRST QUARTER Ablynx NV* (Belgium) Kirin Brewery Co. Ltd. (Japan) Collaboration focused on the use of Nanobodies as therapeutic products Specifics on the research and license agreement were not disclosed (2/9) Ablynx NV* (Belgium) Novartis AG (Switzerland) Deal to to discover and develop Nanobody-based drugs against a number of targets in a range of diseases Ablynx gets up-front fees, license
State of the Industry Report | Thursday, May 24, 2007
Underwriter (Number of IPOs As Lead Underwriter) Gross Proceeds (M) Bear, Stearns & Co. (1) $44.9 Jefferies & Co. (1) $38.5 First Albany Capital (1) $20.1 Stifel Nicolaus (1) $20.1 Roth Capital Partners (1) $10.2 Sunrise Securities (1) $10.2